Orchid Pharma Limited
Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs.
What Orchid files
- Others47
- Investor Meet27
- Important22
- Board Meeting13
- Updates6
- PPTs5
Orchid Pharma presented a mixed financial performance. Q4FY26 revenue was stable at ₹238 Cr, with EBITDA up 5% to ₹42 Cr and PAT rising 7% to ₹30 Cr. However, for the full FY26, revenue dropped 12% to ₹811 Cr, EBITDA fell 36% to ₹101 Cr, and PAT decreased significantly to...
Orchid Pharma faced a tough Q2 & H1 FY26. **Business Performance:** Sales for Q2 FY26 dropped 13% YoY to 194 Cr, and H1 FY26 revenue decreased 22% to 366 Cr. Profitability took a significant hit, with Q2 PAT plummeting 92% YoY to 2 Cr, and H1 PAT down 64% to...
**Financial Highlights:** Orchid Pharma's Q1 FY26 financials show a notable decline. Sales were down 29% YoY to 173 Cr. EBITDA dropped 27% to 30 Cr, with PBT and PAT each falling 38% to 18 Cr. Despite the sales decrease, EBITDA margin held steady at 17%, and Gross Margin improved to...
1. Financial Highlights: Orchid Pharma reported sales of ₹922 Cr for FY-25, up 13% YoY, supported by steady business growth. Other income increased 7% to ₹32 Cr. Cost of goods sold rose 12%, with gross margins steady at around 41%. Employee expenses jumped 23%, and other expenses were up 8%....
**Financial Highlights:** Orchid Pharma reported a 12% increase in sales for Q2 FY 2024-25, reaching ₹222.7 Cr, up from ₹198.8 Cr in Q2 FY 2023-24. For the first half, sales increased by 22%, totaling ₹467.1 Cr compared to ₹381.7 Cr in the previous year. EBITDA improved by 20% to ₹37.5...